Development and Novel Uses of Antibodies in Epithelial Ovarian Cancer
Annual rept. 15 Jul 2002-14 Jul 2003
NEW YORK UNIV SCHOOL OF MEDICINE NY
Pagination or Media Count:
Immunologic approaches to treat ovarian cancer, a chemosensitive tumor, are in their infancy and have generally represented isolated clinical trial efforts. Further understanding of the host response to epithelial cancers and the potential capability of innovative immunologic technologies to ovarian cancer may play a key role in therapeutic advances. This integrated program proposes to expand the scope of ovarian cancer treatment in general, and immunotherapy in particular by working in three new and interrelated directions. These include 1 new techniques that may identify relevant new human antibodies and characterize the target antigens, 2 test these in project models to evaluate the potential role in future therapy for ovarian cancer combined with radiation and chemotherapy, and 3 explore their role in allowing for the more accuarate targeting of gene therapy. During the first year of the project, we were able to establish a cohesive working group. IRB approval was obtained. Standard opera procedures regarding collection of lymphatic tissue and transfer to PI for Project 1 were established. Initial work was begun on Project 2 and Project 3.
- Anatomy and Physiology
- Medicine and Medical Research